Anemia resulting from cancer, or its treatment, and from chronic kidney disease (CKD) is an important clinical problem. Evidence suggests that in patients with CKD (especially those on dialysis), ...

Please provide your email address to receive an email when new articles are posted on . During the last 3 decades, only one class of drugs – erythropoiesis-stimulating agents – has been available to ...

Randomized Trial of Coordinated Psychosocial Interventions Based on Patient Self-Assessments Versus Standard Care to Improve the Psychosocial Functioning of Patients With Cancer PURPOSE: To evaluate ...

Oct. 17, 2003 — Despite its effectiveness against anemia, erythropoietin may actually worsen cancer survival in some patients, according to the results of a randomized trial published in the Oct. 18 ...

ACE inhibitor and/or angiotensin receptor blocker therapy increased epoetin requirements. Older age, elevated BMI, and use of ACE inhibitors and/or angiotensin receptor blockers (ARBs) are associated ...

SAN FRANCISCO--(BUSINESS WIRE)--Dosis, a market leader in artificial intelligence-powered precision dosing, announced today the publication of two abstracts to be showcased at the American Society of ...

LOS ANGELES (Reuters) - Medicare officials do not plan at this time to change payment terms for anemia drugs used in kidney patients who are undergoing dialysis. The agency, which is slated to issue a ...

Credit: Getty Images. The approval was based on data from the pivotal phase 3 COMMANDS trial that compared luspatercept to epoetin alfa in 356 patients with anemia and lower-risk MDS. The Food and ...

LOS ANGELES, July 27 (Reuters) - Sales of Amgen Inc.'s Aranesp and Epogen drugs face continued uncertainty ahead of key U.S. government decisions regarding Medicare coverage and safe use for the ...

SAN DIEGO—Epoetin use and hemoglobin (Hb) levels have declined similarly for black and non-black dialysis patients following the advent of Medicare’s system of “bundled” payments for dialysis services ...